Search results
Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future
Motley Fool· 2 years agoSynthetic biology company Ginkgo Bioworks Holdings (NYSE: DNA) is down roughly 80% from its highs...
Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal
Benzinga via Yahoo Finance· 2 years agoGinkgo Bioworks Holdings Inc (NYSE: DNA) agreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock...
Amyris, Inc. (AMRS) Reports Q2 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance· 2 years agoAmyris, Inc. (AMRS) delivered earnings and revenue surprises of -50% and 20.06%, respectively, for...
Cathie Wood's favorite type of stocks still face significant challenges in staging a recovery,...
Business Insider via Yahoo Finance· 2 years agoMarco Bello/Getty; Savanna Durr/Insider Unprofitable growth stocks still face significant headwinds...
GM announces a management shake-up as it loses 2 key executives
Detroit Free Press via Yahoo Finance· 2 months agoGeneral Motors said Tuesday it is losing both its head of manufacturing and its newly hired head of...
Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoOn Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the company's...
Cathie Wood Is Loading Up on These 3 Stocks: Should You?
Motley Fool· 2 years agoWarren Buffett famously stated that it's smart to "be fearful when others are greedy and be greedy...
Celanese (CE) Soars 6%: Is Further Upside Left in the Stock?
Zacks via Yahoo Finance· 2 years agoCelanese (CE) was a big mover last session on higher-than-average trading volume. The latest trend...
Al Gore and Lila Preston question everything in their firm's new climate report
TechCrunch· 8 months agoEvery year for the past seven years, Generation Investment Management, the sustainability-focused...
3 Monster Stocks in the Making to Buy Right Now
Motley Fool· 2 years agoHere's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Ginkgo Bioworks (NYSE: DNA), and Novocure (NASDAQ: NVCR). Prosper Junior Bakiny (CRISPR Therapeutics): Despite tremendous medical progress ...
